Montreal, 13 April 2016 Dear colleagues,
    • WADA issued a Notice to Stakeholders regarding meldonium
    • The Notice provides clarification regarding its inclusion on the Prohibited List; existing excretion studies and those underway; and, the results management and adjudication process
  • It reinforces the principle of strict liability for athletes under the World Anti-Doping Code; and, the assessment of fault under the Code that is the duty of the robust Results Management and Adjudication process

Yesterday, the World Anti-Doping Agency (WADA) issued a Notice regarding meldonium to its stakeholders that are primarily signatories to the World Anti-Doping Code (Code). The Notice provides clarification regarding its inclusion on the Prohibited List; existing excretion studies and those that are underway; as well as guidance regarding the results management and adjudication process. “There is no doubt as to the status of meldonium as a prohibited substance,” said WADA President, Sir Craig Reedie. “There is equally no doubt that the principle of strict liability under the Code; as well as, the well established process for results management and adjudication prevail,” he continued. “Since meldonium was prohibited on 1 January of this year, there have been 172 positive samples for the substance, for athletes across numerous countries and sports,” Reedie said. “Concurrently, there has been a call by stakeholders for further clarification and guidance,” he continued. “WADA recognizes this need -- that meldonium is a particular substance, which has created an unprecedented situation and therefore warranted additional guidance for the anti-doping community.”